- Home
- MHI vs STTK Comparison
MHI vs STTK Comparison
Compare MHI & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHI
- STTK
- Stock Information
- Founded
- MHI 2003
- STTK 2016
- Country
- MHI United States
- STTK United States
- Employees
- MHI N/A
- STTK N/A
- Industry
- MHI Investment Managers
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- MHI Finance
- STTK Health Care
- Exchange
- MHI Nasdaq
- STTK Nasdaq
- Market Cap
- MHI N/A
- STTK 54.4M
- IPO Year
- MHI N/A
- STTK 2020
- Fundamental
- Price
- MHI $9.36
- STTK $1.15
- Analyst Decision
- MHI
- STTK Hold
- Analyst Count
- MHI 0
- STTK 3
- Target Price
- MHI N/A
- STTK $2.00
- AVG Volume (30 Days)
- MHI 98.8K
- STTK 329.2K
- Earning Date
- MHI 01-01-0001
- STTK 11-14-2024
- Dividend Yield
- MHI 4.09%
- STTK N/A
- EPS Growth
- MHI N/A
- STTK N/A
- EPS
- MHI 0.04
- STTK N/A
- Revenue
- MHI N/A
- STTK $6,435,000.00
- Revenue This Year
- MHI N/A
- STTK $313.04
- Revenue Next Year
- MHI N/A
- STTK N/A
- P/E Ratio
- MHI $219.25
- STTK N/A
- Revenue Growth
- MHI N/A
- STTK 382.75
- 52 Week Low
- MHI $6.93
- STTK $0.94
- 52 Week High
- MHI $9.05
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- MHI 36.62
- STTK 46.55
- Support Level
- MHI $9.46
- STTK $1.07
- Resistance Level
- MHI $9.52
- STTK $1.19
- Average True Range (ATR)
- MHI 0.09
- STTK 0.14
- MACD
- MHI -0.03
- STTK 0.00
- Stochastic Oscillator
- MHI 2.56
- STTK 36.11
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.